The head of pharmaceutical giant GlaxoSmithKline, Andrew Witty, has announced his retirement after a decade as CEO.
The search for a successor comes amid months of pressure from some investors, who had wanted the diverse company to be broken up.
The company said in a statement that Witty believes “this will be the right time for a new leader to take over.” The move is effective in March 2017.
Like many big pharmaceutical companies, GSK has struggled to see off the challenge of generic drugmakers and come up with new blockbuster drugsto replace medicines with expiring patents.
It has also faced other challenges. Britain’s competition authority has fined GSK 37.6 million pounds ($54.5 million) for stalling the potential entry of generic competitors of anti-depressant drug Seroxat into the marketplace.
Filed Under: Drug Discovery